Portfoliotracker

Alector, Inc.

ALEC · NASDAQGS · Healthcare Biotechnology 75/100 B

2,570 $
▲ +0,030 (+1,18 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:05
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score75 / 100 Market cap289 mil. $ P/E7,3 Forward P/E-3,8 P/S1,7 P/B2,5 EV/EBITDA3,8 Dividend yield– FCF yield-51,90 % EPS0,37 $ Net margin23,9 % Return on equity47,5 % Beta0,61 Debt / equity0,18
52-week range 1,09 to 2,84
3-month average volume3,4 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Employees
103
Country
United States
Fiscal year end
31. 12.
Data since
7. 2. 2019

Explore further

Similar companies STOKDNLIBDTXDTIL

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account